US Stock MarketDetailed Quotes

CLYM Climb Bio

Watchlist
  • 3.090
  • -0.060-1.90%
Close Dec 4 16:00 ET
  • 3.090
  • 0.0000.00%
Post 20:01 ET
207.72MMarket Cap-1817P/E (TTM)

About Climb Bio Company

Climb Bio, Inc. operates as a clinical-stage biotechnology company. It develops therapeutics for patients with immune-mediated diseases. Its lead product candidate, budoprutug, is an anti-CD19 antibody designed for a broad range of B-cell mediated diseases. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Wellesley Hills, MA.

Company Profile

SymbolCLYM
Company NameClimb Bio
Listing DateAug 10, 2021
Issue Price12.50
Founded2018
CEODr. Aoife M. Brennan, M.B.
MarketNASDAQ
Employees11
Fiscal Year Ends12-31
Address20 William Street,Suite 145
CityWellesley Hills
ProvinceMassachusetts
CountryUnited States of America
Zip Code02481-4103
Phone1-866-857-2596
Websitehttp://www.climbbio.com

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Stephen Thomas, PhD
  • Interim Chief Executive Officer and Director
  • --
  • Dr. Aoife M. Brennan, M.B.
  • President, Chief Executive Officer and Director
  • --
  • Emily Pimblett
  • Chief Accounting Officer
  • --
  • Dr. Brett Kaplan, M.D.
  • Chief Operating Officer and Principal Financial Officer
  • --
  • Dr. Andrew Levin, M.D.,PhD
  • Chairman of the Board
  • 87.91K
  • Stephen Thomas
  • Director
  • --
  • Simon Tate
  • Independent Director
  • 22.52K
  • Adam Rosenberg
  • Independent Director
  • 77.16K
  • Dr. Judith A. Dunn, PhD
  • Independent Director
  • 69.66K
  • Dr. Liam Ratcliffe, M.D.,PhD
  • Lead Independent Director
  • 71.33K
  • Dr. Jan L. Hillson, M.D.
  • Senior Clinical Advisor
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data